肠道菌群在免疫检查点抑制剂治疗肿瘤中作用的研究进展

Tracking Research Progress in the Modulatory Role of Gut Microbiome in Immune Checkpoint Inhibitors Applied in Cancer Treatment

近年来,免疫疗法作为抗肿瘤新兴治疗方法,在实体瘤和血液系统肿瘤中均展现出极大的治疗潜力。越来越多的临床前和临床证据将肠道微生物组成与免疫检查点抑制剂抗肿瘤疗效及不良反应联系起来。本文对肠道微生物在不同免疫检查点抑制剂抗肿瘤治疗中的调控作用进行综述,并对目前研究的局限性及进一步临床策略的发展进行展望。

In recent years,immunotherapy,as an emerging anti-tumor therapy,has shown great potential in the treatment of both solid and hematologic tumors.There is increasing preclinical and clinical evidence linking the composition of gut microbiome with the efficacy as well as adverse effects of immune checkpoint inhibitor anti-tumor therapy.We summarized in this review the modulatory role of the gut microbiome in antitumor therapy with different immune checkpoint inhibitors.We also discussed the limitations of existing research and prospective development of the further clinical strategies.